Diaceutics PLC

In this 20 minute on-demand expert insights session, Diaceutics’ precision medicine experts break down the key challenges shaping the industry today and the latest advancements shared at ESMO 2025 enabling you to stay on top of the latest news.

In this on-demand expert insights session, Diaceutics’ precision medicine experts break down the key challenges shaping the industry today and the latest advancements shared at ESMO 2025 enabling you to stay on top of the latest news. Watch on-demand today.

In this on-demand expert insights session, Diaceutics’ precision medicine experts break down the key challenges shaping the industry today and the latest advancements shared at ESMO 2025 enabling you to stay on top of the latest news. Watch on-demand today.

From Blockbusters to Biomarkers: Rethinking Commercialization for the Precision Era It’s clear that for precision medicines, the traditional blockbuster model for commercialization is out of sync with its needs. Traditional models, built for broad and undifferentiated populations, are often costly and poorly aligned with the specific needs of therapies targeting biomarker-defined patient group. Innovation Has Outpaced Commercialization Despite rapid advances in precision medicine, commercialization strategies have struggled to keep pace. The persistent assumption that diagnostic testing will naturally follow a drug launch has proven wrong. Without early, intentional alignment among pharma, diagnostics, labs, and physicians, testing lags behind and eligible patients remain undiscovered. Traditional models, reliant on large sales teams and broad awareness campaigns, are increasingly ineffective at reaching physicians at the critical moment of decision-making. The financial burden is immense and untenable for precision therapies. As a result, we’re seeing promising treatments being deprioritized, abandoned, or returned to licensors, not due to clinical shortcomings, but because the commercial model cannot support their targeted nature. The Case for Change: Enter Targeted Commercialization This growing disconnect calls for a different approach, one as precise as the therapies it supports. Targeted Commercialization, pioneered by Diaceutics, is a strategic partnership designed to ensure that groundbreaking treatments reach those who need them most, efficiently and effectively. What Makes Targeted Commercialization Different? - Strategic Partnership, Not Just a Service: Targeted Commercialization is rooted in collaboration and deeply understanding the needs of each asset. - Powered by Real-World Data: Leveraging proprietary multi-modal and real-time data, this model provides a dynamic, actionable view of the testing and treatment landscape. - Persona-Driven Engagement: Lab and physician stakeholders are engaged both digitally and personally, with relevant, timely and persona driven messaging. - Cost-Efficient, Flexible Models: Milestone-based and success-based pricing aligns costs with impact, preserving cash runway and de-risking commercialization for biopharma partners. The Bottom Line At Diaceutics, we believe commercialization should be as precise as the therapies it supports. And with Targeted Commercialization, we’re proving that it can be. Let’s build the future of precision medicine together! #PrecisionMedicine #DataDrivenImpact #PatientImpact #Diaceutics

🚦How do we turn budget roadblocks into commercialization green lights? As the industry moves toward increasingly tailored treatments, it’s clear that traditional commercialization models aren’t necessarily suitable to support precision medicines. To truly unlock the potential of precision medicine, we must apply a precision lens to commercialization itself. If the patient population is more specific, shouldn’t the commercial strategy and tactics be too? 💰Traditional Commercialization is too expensive Traditional commercialization relies on broad campaigns, large sales teams, and extensive infrastructure, often costing up to and over $1 billion annually, especially in launch years. While this may work for blockbuster drugs, it’s misaligned with the needs of precision therapies targeting narrower populations. For biotechs and smaller pharma, these costs can be prohibitive but by leveraging the right data, strategies, and targeted engagement capabilities, it doesn’t have to be. 💸 Targeted Commercialization Is More Effective and Cost-Efficient Targeted commercialization uses real-world data and analytics to understand, engage and prepare the market for testing, finding patients and engaging physicians and labs in a relevant, timely and tailored way. This means resources are focused where they have the greatest impact, reducing spend on low-yield activities. ⌛Targeted commercialization enables “just-in-time” engagement - reaching stakeholders at the exact moment they are making testing or treatment decisions. This increases the likelihood of therapy adoption and ensures that educational resources are delivered when most relevant. Instead of front-loading costs, targeted commercialization aligns investment with product milestones and commercial success. When you partner you can pay for results, not just for tactics. This approach is especially valuable for smaller biotechs and pharma where preserving the cash runway is critical and where every dollar counts. 🧠 A Smarter Path Forward: Precision Commercialization At Diaceutics, we advocate for an approach that is: Data-driven: Leveraging real-world data to identify eligible patients, guide engagement, and track adoption. Targeted: Reaching the right physicians, pathologists, and labs at the right time, with the right message through digital and personal peer-to-peer channels. Cost-effective: Delivering measurable impact at a fraction of traditional costs. With room for alternative commercial models e.g. milestone/success based pricing. Diaceutics has developed a commercialization model designed to drive testing, promote biomarker awareness, accelerate therapy adoption, and deliver impact - without the blockbuster price tag. Because every missed test could mean a missed patient. And every missed patient is a missed opportunity to improve a life. 🚀Let’s build the future of precision medicine together! #PrecisionMedicine #RealWorldData #PatientImpact #Diaceutics

🔬 Precision medicine is advancing rapidly, bringing transformative therapies to market that can dramatically improve patient outcomes. NTRK therapies show up to a 75% overall response rate in NTRK fusion-positive tumors, with a duration of response up to 35 months and progression-free survival of 28 months. So why are patients still missing out on these therapies? The problem isn’t the science. 📙Precision Medicine Needs a New Commercial Playbook At a very basic level, success in precision medicine depends on the coordinated efforts of three key stakeholders each with their own focus: 1. Biopharma: Drives innovation by developing and launching new therapies. 2. Labs: Advance diagnostic capabilities and efficiency. 3. Physicians: Diagnose and treat patients. To realize precision medicine’s potential, we must boost testing, raise biomarker awareness, and connect therapies to eligible patients. This demands coordinated effort & behavioral change – which is often under-resourced and hard to incentivize. ⚠️ Without early alignment, testing lags - and patients miss out. 📩Innovation Overload: The Engagement Challenge Physicians face a constant influx of new therapies, protocols, and guidelines – all while staying focused on patient care. Static, generic education often gets ignored. To truly engage, education must be timely, relevant, and actionable. 🎯The Ideal Precision Commercialization Model Launching targeted therapies presents unique challenges, but also unique opportunities. 🧠 Imagine a world where you have testing data at your fingertips. You have a clear strategic roadmap and a partner to help you execute your tactics. You know where eligible patients are being treated and who they’re being treated by. You can engage pathologists, labs, and physicians on who, how, and when to test. Better yet, you can provide them with peer-to-peer support to further drive awareness. That’s the goal. 💡 A new commercialization model for precision medicine must: - Engage all key stakeholders to accelerate test readiness and biomarker awareness before launch. - Apply a precision lens to commercialization - focusing on both the testing and the treatment. - Use real-world data (RWD) to identify eligible patients and guide engagement: tailored, timely, data-driven digital with complementary personal engagement. - Track the success of tactics across engagement, testing rates, conversion, and adjust accordingly. 💸 And ideally a new model needs to achieve all this for a fraction of the cost required by traditional models! Great medicines aren’t reaching their true potential. This isn’t just a commercial imperative, it’s critical for patients. Every missed test is a potential missed patient. 🚀Let’s build the future of precision medicine together! 💬 Share your thoughts, experiences, or perspectives in the comments. #PrecisionMedicine #RealWorldData #PatientImpact #Diaceutics